BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18191201)

  • 21. Pentostatin in chronic lymphocytic leukemia.
    Sauter C; Lamanna N; Weiss MA
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1217-22. PubMed ID: 18721115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging therapies for patients with advanced chronic lymphocytic leukaemia.
    Delgado J; Briones J; Sierra J
    Blood Rev; 2009 Sep; 23(5):217-24. PubMed ID: 19643519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in chronic lymphocytic leukemia.
    Abbott BL
    Cancer Invest; 2006; 24(3):302-9. PubMed ID: 16809159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial therapy for patients with chronic lymphocytic leukemia.
    Wierda WG; O'Brien SM
    Semin Oncol; 2006 Apr; 33(2):202-9. PubMed ID: 16616067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic lymphocytic leukemia in the young patient.
    de Lima M; O'Brien S; Lerner S; Keating MJ
    Semin Oncol; 1998 Feb; 25(1):107-16. PubMed ID: 9482532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
    Dungarwalla M; Evans SO; Riley U; Catovsky D; Dearden CE; Matutes E
    Haematologica; 2008 Mar; 93(3):475-6. PubMed ID: 18310545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.
    Byrd JC; Lin TS; Grever MR
    Semin Oncol; 2006 Apr; 33(2):210-9. PubMed ID: 16616068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.
    Grever MR; Lucas DM; Johnson AJ; Byrd JC
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):545-56. PubMed ID: 17707839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
    Brugiatelli M; Bandini G; Barosi G; Lauria F; Liso V; Marchetti M; Mauro FR; Meloni G; Zinzani PL; Tura S; ; ;
    Haematologica; 2006 Dec; 91(12):1662-73. PubMed ID: 17145603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
    Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
    J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current approach to diagnosis and management of chronic lymphocytic leukemia.
    Shanafelt TD; Call TG
    Mayo Clin Proc; 2004 Mar; 79(3):388-98. PubMed ID: 15008611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
    Bouzar AB; Boxus M; Defoiche J; Berchem G; Macallan D; Pettengell R; Willis F; Burny A; Lagneaux L; Bron D; Chatelain B; Chatelain C; Willems L
    Br J Haematol; 2009 Jan; 144(1):41-52. PubMed ID: 19006566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current guidelines in defining therapeutic strategies.
    Ferrajoli A; Keating MJ
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):881-93, ix. PubMed ID: 15325704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic lymphocytic leukemia.
    Ghia P; Ferreri AM; Caligaris-Cappio F
    Crit Rev Oncol Hematol; 2007 Dec; 64(3):234-46. PubMed ID: 17544290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic lymphocytic leukemia: diagnosis and treatment.
    Yee KW; O'Brien SM
    Mayo Clin Proc; 2006 Aug; 81(8):1105-29. PubMed ID: 16901035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
    Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
    Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Waldenström's macroglobulinemia: prognostic factors and recent therapeutic advances.
    Leblond V; Tournilhac O; Morel P
    Clin Exp Med; 2004 Apr; 3(4):187-98. PubMed ID: 15103509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
    Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
    Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL.
    Klepfish A; Rachmilewitz EA; Kotsianidis I; Patchenko P; Schattner A
    QJM; 2008 Sep; 101(9):737-40. PubMed ID: 18650226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.